Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Daniel Cantillon

Cardiovascular Disease Cleveland, OH Medical Doctor

NPI 1508030024 CMS profile 1089208

9500 Euclid Ave, Desk J2-2, Cleveland, OH 44195

Open in the dashboard

General payments

$140,365

230 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,137,372 paid to institutions, not to them · program years 2019–2024

Through program year 2024, Daniel Cantillon of Cleveland, OH is reported in the CMS Open Payments database as having received $140,365 across 230 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,137,372 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $23 1
2023 General $6,093 10
2022 General $60,651 81
2021 General $31,798 58
2020 General $12,984 21
2019 General $28,815 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Cantillon
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Daniel Cantillon were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Daniel Cantillon Cardiovascular Disease median Middle half National median
2019 $28,815 $450 $127–$1,392 $163
2020 $12,984 $242 $77–$751 $114
2021 $31,798 $335 $101–$1,037 $132
2022 $60,651 $395 $121–$1,211 $149
2023 $6,093 $443 $136–$1,283 $160
2024 $23 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Abbott Laboratories $66,823 120 payments
  2. Boston Scientific Corporation $51,707 77 payments
  3. Masimo Corporation $18,766 24 payments
  4. Stryker Corporation $2,123 6 payments
  5. Biosense Webster, Inc. $899 2 payments
  6. Impulse Dynamics (USA) Inc. $48 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $77,365 70 payments
  2. Travel and Lodging $29,191 91 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,000 7 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $9,900 8 payments
  5. Food and Beverage $4,159 52 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $2,750 2 payments
Products named General payments · program years 2019–2024
  1. Ensite Cardiac Mapping System $12,815 22 payments
  2. CLINICAL TRIAL PRODUCT Clinical Trial Product $12,518 13 payments
  3. CLINICAL TRIAL PRODUCT Pain Management $12,430 13 payments
  4. SedLine $10,140 13 payments
  5. ENSITE PRECISION $7,331 13 payments
  6. General - Therapies $6,641 10 payments
  7. AVEIR $6,335 8 payments
  8. HeartMate $5,806 4 payments
  9. ACCENT $4,715 2 payments
  10. Nanostim Leadleas Pacemaker $4,482 11 payments
  11. Other $42,595 96 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

230 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record